

This week in therapeutics

| Indication | Target/marker/pathway | Summary | Licensing status | Publication and contact information |
|---|---|---|---|--|
| Cancer | | | | |
| Lung cancer | Catenin (cadherin-associated protein) δ 1 (CTNND1; p120) | Studies in primary human tumors, in cell culture and in mice suggest that inhibiting CTNND1 could help treat lung cancer. Compared with normal control cells, in primary human lung tumors CTNND1 was upregulated. Lung endothelial cells from <i>Ctnnd1</i> knockout mice had impaired angiogenic properties. Murine lung tumors from <i>Ctnnd1</i> knockout mice had slower growth than tumors from wild-type controls. Next steps could include identifying and testing CTNND1 inhibitors. | Patent and licensing status undisclosed | DeBusk, L. <i>et al.</i> <i>J. Exp. Med.</i> ; published online Jan. 4, 2010; doi:10.1084/jem.20091097 Contact: P. Charles Lin, Vanderbilt University Medical Center, Nashville, Tenn. e-mail: charles.lin@vanderbilt.edu |
| <p><i>SciBX</i> 3(6); doi:10.1038/scibx.2010.181 Published online Feb. 11, 2010</p> | | | | |